Investor information

Welcome to the Investor Relations section of the Verona Pharma website

This area is dedicated to keeping shareholders and potential investors up to date with our news, share price, and other relevant information.

We are committed to delivering our strategy and creating both near-and long-term value to our shareholders.

AIM

NASDAQ

Latest press releases

  • Accelerates top-line data readouts from ongoing clinical trials with RPL554 in COPD and CF LONDON , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ( Verona Pharma ), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative
  • LONDON , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on November 29, 2017 , Dr.

Latest video

 

IR contacts

US Investor relations contact
ICR, Inc.
E: ICR_Verona@icrinc.com
T: +1 646-277-1282

UK Investor relations contact
FTI Consulting
E: veronapharma@fticonsulting.com
T: +44 (0)20 3727 1000